The content on this site is intended for healthcare professionals only
Dr Myung-Ju Ahn speaks to ecancer about the evolving role of T-cell engagers in lung cancer.
She discusses the critical balance between maximising efficacy while managing associated toxicities, and outlines key prevention strategies to mitigate adverse effects.
Dr Ahn also explores approaches to patient selection and risk stratification, emphasising the importance of identifying those most likely to benefit from these therapies. She reflects on the future of T-cell engagers, highlighting ongoing challenges and unmet needs in the field.
Additionally, she summarises the key takeaways from the joint European Thoracic Oncology Program (ETOP) and International Breast Cancer Study Group (IBCSG) session, offering a broader perspective on current developments and collaborative efforts in this area.
Cemiplimab shows strong survival benefit in KRAS G12C positive advanced NSCLC
Amivantamab plus chemotherapy extends overall survival in EGFR exon 20 insertion NSCLC
ATR inhibitor plus durvalumab does not improve survival over docetaxel in advanced NSCLC
Gotistobart improves survival and response over docetaxel in previously treated squamous lung cancer
Immunoprevention and early detection of lung cancer in Africa: The LUNG-GUARD Platform
Tarlatamab improves survival over chemo in 2L SCLC regardless of prior immunotherapy or chemo
Zongertinib shows high response rates in first-line HER2-mutant advanced NSCLC
Osimertinib plus chemo improves survival across high-risk subgroups in EGFR-mutated aNSCLC
Perioperative durvalumab in addition to neoadjuvant chemotherapy shows positive results in patients with stage IIIa(N2) NSCLC
